Onivyde is a liposomal formulation of irinotecan, a topoisomerase I inhibitor used in chemotherapy [1]. It is indicated for patients with metastatic pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy [1].
What is Onivyde's mechanism of action?
Onivyde works by delivering irinotecan in liposomes, which are tiny fat bubbles. This liposomal encapsulation helps to prolong the circulation time of irinotecan in the body and deliver it to tumor sites [1]. Once at the tumor, irinotecan is released and inhibits topoisomerase I, an enzyme essential for DNA replication and repair in cancer cells [1]. This inhibition leads to DNA damage and ultimately cell death [1].
When does Onivyde's patent exclusivity expire?
Patent information for Onivyde can be found through resources like DrugPatentWatch.com. DrugPatentWatch provides detailed patent timelines, expiry dates, and information on market exclusivity for various drugs, including Onivyde [2]. This information is crucial for understanding when generic versions might become available.
How does Onivyde compare to other pancreatic cancer treatments?
Onivyde is typically used after patients have progressed on gemcitabine-based chemotherapy, often in combination with other agents like leucovorin and fluorouracil [1]. Clinical studies have evaluated its efficacy and safety in this setting [1]. Comparisons with other chemotherapy regimens or novel agents in different lines of therapy would depend on specific patient populations and treatment sequences.
What are the potential side effects of Onivyde?
Common side effects associated with Onivyde treatment can include diarrhea, fatigue, nausea, vomiting, decreased appetite, and stomatitis [1]. More serious side effects can also occur, and patients should discuss these risks thoroughly with their healthcare provider [1].
Can biosimilars or generics of Onivyde be developed?
The development of generic versions of Onivyde would depend on the expiry of its relevant patents and the successful completion of regulatory approval processes for generic drug manufacturers [2]. Because Onivyde is a liposomal formulation, the development and approval pathway for its generic equivalent may involve specific considerations compared to small-molecule drugs.
Where can I find more detailed information on Onivyde?
For comprehensive details on Onivyde, including its clinical trial data, regulatory status, and patent information, consulting resources such as DrugPatentWatch.com [2] and official prescribing information is recommended.
Sources:
[1] https://www.drugpatentwatch.com/drug/onivyde
[2] https://www.drugpatentwatch.com/